Clinical Trials
26 trialsPediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
St. Jude Children's Research Hospital
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
M.D. Anderson Cancer Center
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
M.D. Anderson Cancer Center
Allogeneic Stem Cell Transplant for CLL
M.D. Anderson Cancer Center
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants
The Hospital for Sick Children
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Stanford University
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
St. Petersburg State Pavlov Medical University
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Columbia University
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Northwestern University
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Weill Medical College of Cornell University
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Stanford University
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Indiana University
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
Columbia University
High Risk
New York Medical College
Pilot Study of Unrelated Cord Blood Transplantation
King's College Hospital NHS Trust
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation
Washington University School of Medicine
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
University of Virginia
Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor
M.D. Anderson Cancer Center
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
M.D. Anderson Cancer Center